Using ZNF419, TUBE1, STEAP3, SLC1A4, RRM2, PTGS2, MT1G, MAP3K5, DDIT4, CAPG, CAV1, BAP1, AURKA, and ATG4D, Jiang et al. designed a prognostic FRGs risk model, in which it was shown that expression levels of PTGS2, RRM2, AURKA, CAV1, MAP3K5, and STEAPS are higher in tumor samples, and the upregulation of PTGS2 and the downregulation of MT1G, TUBE1, and ATG4D might contribute to tumorigenesis and poor outcomes [57]. The gene discussed is ATG4D; the disease is neoplasm.